Schizophrenia study: Valbenazine
Official title A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
ClinicalTrials.gov ID: NCT07105111
What this study is testing
What is Valbenazine?
Valbenazine is an investigational oral capsule being studied as a potential treatment for tardive dyskinesia in people with schizophrenia.
Also referred to as NBI-98854.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether valbenazine improves movement problems in adults with tardive dyskinesia. It looks at how well it works for people still on or after stopping a VMAT2 inhibitor.
- Who it's for
- You may be able to join if you are an adult with tardive dyskinesia and you are still having symptoms while taking or after stopping a VMAT2 inhibitor.
- What's involved
- You would take valbenazine and have visits where doctors and you report how your movements feel. You may also do some simple tests.
- Time commitment
- The study lasts about 6 months and includes several clinic visits.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 18 years of age or older
- Diagnosed with one of the following at least 3 months prior to screening: schizophrenia or schizoaffective disorder, bipolar disorder, or major...
- Diagnosed with at least mild neuroleptic-induced TD for at least 3 months prior to screening Key
You likely can't join if
- Have comorbid Parkinsonism or abnormal involuntary movement(s) that is more prominent than TD
- Diagnosis of moderate or severe substance use disorder in the last 6 months
- History of long QT syndrome, cardiac arrythmia, or severe hepatic impairment
The study team makes the final eligibility decision.
Where it is enrolling
- Bryant, Arkansas, United States
- Chino, California, United States
- Fresno, California, United States
- Long Beach, California, United States
- Orange, California, United States
- Redlands, California, United States
- San Diego, California, United States
- Bonita Springs, Florida, United States
- Hialeah, Florida, United States
- Miami, Florida, United States
- Orange City, Florida, United States
- Port Charlotte, Florida, United States
- Tampa, Florida, United States
- Augusta, Georgia, United States
- Naperville, Illinois, United States
- Omaha, Nebraska, United States
- Independence, Ohio, United States
- Austin, Texas, United States
- Richmond, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Bryant, Arkansas, United States; Chino, California, United States; Fresno, California, United States; Long Beach, California, United States; Orange, California, United States; Redlands, California, United States and 13 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.